The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.
This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.
Arnt Kristen studied medicine at the Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany, obtaining his MD degree in 2001. He completed his residency in internal medicine at the Department of Internal Medicine, University Hospital, Heidelberg, Germany. He received board certifications for internal medicine and cardiology in 2008 and 2010, respectively. He received a degree in business administration in 2008. Prof. Dr. Kristen currently works as a cardiologist at the Heidelberg Heart Centre and Heidelberg Amyloidosis Centre at the University of Heidelberg and at the Cardiovascular Centre Darmstadt.
Prof. Dr. Kristen’s scientific and clinical focus is on cardiomyopathies and rare diseases, as well as the management and treatment of these disorders, including heart transplantation. His particular emphasis is on cardiac amyloidosis, and another clinical interest is the field of interventional cardiology.
Prof. Dr. Kristen is a member of the German Society of Cardiology and the German Society for Amyloid Diseases. He is an investigator in several clinical trials focused on the treatment of hereditary amyloidosis. Moreover, he served as a consultant for cardiac amyloidosis and is author of more than 50 peer-reviewed publications in national and international journals with focus on cardiac amyloidosis.
Mathew Maurer
Columbia University, New York, United States
Mathew Maurer is a general internist and geriatric cardiologist with advanced training in heart failure and cardiac transplantation. He is the Arnold and Arlene Goldstein Professor of Cardiology at Columbia University Irving Medical Center, Vagelos College of Physicians & Surgeons, where he directs the Clinical Cardiovascular Research Laboratory for the Elderly (CCRLE). He is also a member of the Advanced Cardiac Care Center at New York Presbyterian Hospital – Columbia Campus.
Dr. Maurer has published over 300 articles, including peer-reviewed manuscripts, reviews, and book chapters. He was chair of the American College of Cardiology’s Geriatric Cardiology Member Section, which is the largest organization dedicated to advancing the care of older adults with cardiovascular disease. He was co-chair of the steering committee of the ATTR-ACT trial showing tafamidis was a safe and effective therapy for transthyretin amyloid cardiomyopathy. Throughout his career, he has promulgated an approach to older adults with cardiovascular disease that offers the best of both geriatric and cardiovascular medicine in which a comprehensive holistic approach to enhance functional capacity and quality of life is at the forefront of emerging techniques to address cardiovascular physiologic derangement that disproportionately affect older adults.
Marianna Fontana
University College London, London, United Kingdom
Marianna Fontana is the director of the University College London (UCL) CMR unit at the Royal Free Hospital. She is professor of cardiology and honorary consultant cardiologist at the National Amyloidosis Centre, University College London, where she is deputy head of the Centre and deputy clinical lead. Prof. Fontana obtained her medical degree (MD) and qualifications as a cardiologist at the University of Pisa. She undertook a PhD at UCL which focused on CMR in cardiac amyloidosis. Her main research interests are cardiac imaging, amyloidosis, and heart failure. She is an intermediate British Heart Foundation Fellow and has co-authored 210 peer reviewed publications with more than 12,900 citations.